Graphite Bio, Inc. (NasdaqGM: GRPH) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Graphite Bio, Inc. (NasdaqGM: GRPH) with LENZ Therapeutics. Under the terms of the proposed transaction, Graphite shareholders will end up owning approximately 35% of the combined company, subject to possible adjustment. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.